Peer Review History
Original SubmissionAugust 25, 2021 |
---|
PONE-D-21-25105 Prevalence and associated risk factors of HIV infections in a representative transgender and non-binary population in Flanders and Brussels (Belgium): Protocol for a community-based, cross-sectional study using time-location sampling PLOS ONE Dear Dr. De Brier, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Feb 24 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Hong-Van Tieu Academic Editor PLOS ONE Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. Additional Editor Comments: Thank you for submitting this manuscript “Prevalence and associated risk factors of HIV infections in a representative transgender and non-binary population in Flanders and Brussels (Belgium): Protocol for a community-based, cross-sectionals study using time-location sampling” which seeks to recruit a representative sample of transgender and non-binary adults in Belgium and determine the HIV prevalence in the community. The reviewers found that this topic represents important work and roadmap for creating representative samples of TGNB people in other regions. Reviewer comments are included, which will require revision for consideration for acceptance for publication. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions? The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses? The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable? Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors described where all data underlying the findings will be made available when the study is complete? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics. You may also provide optional suggestions and comments to authors that they might find helpful in planning their study. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Very competent and detailed report of planned study methods for a survey to estimate HIV prevalence in transgender and non-binary people in Flanders and assess associated risk factors. There are two points where more information is needed, in my opinion. (A) Calculation of the sizes of clusters and thus the sampling fractions. Line 554 ‘Sampling fraction (number of participants out of total number of eligible attendees at the cluster)’ – how will the total eligible numbers be determined or estimated for these diverse types of clusters (‘medical, mental health and social services, pride events, bars, discussion groups, social media groups, online fora,’)? Especially as ‘eligible’ means TGNB, is this realistic? Cluster sizes are required for the systematic sampling of clusters and for weighting during estimation. (B) Line 491: Selection of people in digital clusters is ‘based on available list of group/forum members’ – do such lists exist for all these various types of cluster? Will it be possible to create the list of TGNB people in advance, or will this eligibility criterion be determined by questioning the individual people? In view of the potential biases associated with the TLS sampling method, which are appropriately discussed by the authors, I wondered whether a simple random sample from the Flanders population might be feasible and maybe more reliable. According to the figure given in lines 267-272, around 40 000 questionnaires would need to be sent out in order to find 1000 TGNB people. This is of course only possible if complete lists of inhabitants with contact details are accessible. Even if this alternative method cannot be fully implemented, a smaller such sample might serve as a check on the completeness and representativeness of the main TLS sampling method. Could the authors comment on this? Minor points: 1. Line 320-321: The proportions with HIV are p0, p1 (lower-case), while the proportions with and without the risk factor are P0, P1 (upper-case) – so in these lines it should be lower-case p0, p1? 2. Line 322 ‘Since the risk factor will be assessed at the level of the individual TGNB people, the use of the design effect for clustering is a conservative approach here.’ – is that so? 3. Line 566 Logistic models are fitted ‘incorporating clustering’ – does this mean that cluster is fitted as an explanatory factor and therefore estimates of HIV prevalence per cluster will be calculated? Or does it mean that a kind of ‘mixed model’ is used to allow for random cluster effects? 4. Line 675 ‘The TLS methodology will not allow for inference from a geographically or demographically defined sample’ – meaning unclear to me. 5. A few minor language corrections need to be made, e.g. lines 467 'into French', 491 'time slots', 560 'nine variables will be questioned': do you mean queried or analysed?, 595 'determined to a large extent by', 602 'as well as possible. In line 563 do you mean 'confounding factors' or 'explanatory factors'? Reviewer #2: The study “Prevalence and associated risk factors of HIV infections in a representative transgender and non-binary population in Flanders and Brussels (Belgium): Protocol for a community-based, cross-sectionals study using time-location sampling” seeks to recruit a representative sample of transgender and non-binary (TGNB) adults in Belgium and determine the HIV prevalence in this community. Given the nascent nature of public health-related research with this population, and its to-date focus on high-risk members of the community (including sex workers) or clinic-based samples. As such, this is important work and can help create a roadmap for creating representative samples of TGNB people in other places. I do have some concerns, however. A general note: Throughout the paper there are slight translation and idiomatic issues that I think could use the benefit of an editor. For example, in line 38, the phrase “transgender women being people” reads more easily as “transgender women are people” with a similar comment for transgender men on the next line (line 39). Another example can be found in line 85, “It becomes clear that as long as gender identity is not taking into account” should read “It becomes clear that as long as gender identity is not taken into account”. Finally, in line 602, “information bias should be as good as possible” should be “information bias as well as possible”. Major Concerns 1. In a number of places in the introduction, you use the phrase “HIV prevalence has been estimated high for transgender people” or similar phrasing. I think you would make a stronger argument if you introduced the prevalence ranges you cite earlier in the introduction. Further, it is not clear (without presenting the data) if you are making absolute statements or comparing HIV prevalence to other groups. 2. In lines 55-58, the language that you use to describe possible mechanisms for the effects of stigma and discrimination feels stigmatizing. Facing stigma and discrimination are associated with HIV risk behavior but focusing solely on potential individual-level mechanisms (low self-esteem, mental health, a need for affirmation from others) instead of more structural factors (or ignoring the structural factors altogether) reads as a stigmatizing statement. Perhaps TGNB who face discrimination cannot negotiate safe sex because of (or in part) marginalization. They could lack the power to negotiate safer sex. The structural issues could be less of a factor in Belgium than in other countries, but this part of the introduction reads as a more global comment. 3. One of the arguments made is that most research is conducted among transgender women. Some quantification of this (you use the phrase “a lot” in line 65) would be helpful. What proportion of studies focus on transgender women? Further, in the next sentence, the point is made that most research among TGNB is conducted in large sexual health clinics and community centers, which leads to samples that are disproportionately at high risk for HIV. This seems to be missing citations. 4. In the introduction the authors criticize other work for taking place mainly in large, urban, population centers. Yet, in the TLS scheme, the authors select Brussels and Flanders rather than a broader survey of Belgium. Some (even brief) discussion of how much of the population is included in this region or some of the rationale for location choices would be helpful. Especially as the objective is to create a representative sample of TGNB residing in a Western European country. The addition of digital LGBT+/TGNB spaces may penetrate into other regions, but some discussion would be clarifying. 5. The authors refer to their study as a CBPR study, but it is unclear exactly what that means. While it is undoubtedly a community-based study, CBPR requires more and it is not clear what leadership or major roles members of the TGNB community or supporting organizations actually play. For example, are members of the TGNB study co-investigators or parts of a Community Advisory Board (CAB)? Did they play a role in the design of the study or survey? In what ways are members of the community driving the research or research question? How are members of the community partners in this study as opposed to participants only? 6. In the methods section, it is unclear why a cluster is expected to be on average 18 TGNB. This seems large for a cluster, even for estimation purposes. I think that a hypothetical situation (a single event or cluster would be defined as xxx location for yyy hours, yielding approximately zzz contacts) would be helpful. 7. In lines 353-354, the authors state that the number of TGNB…will be fixed at 50% of the total…events. Does this mean that 50% of TGNB particopants will be recruited from healthcare settings and the remaining 50% from outreach events? It currently reads as though TGNB will be 50% of those sampled. 8. In the description of variables section, the terms transvestite and cross-dresser are offered as gender identity options. This may be a country-specific issue (different terms used across countries), but these terms seem both anachronistic and not to measure gender identity. 9. In the selection and data collection procedures section (lines 491), it is unclear how privacy issues around data collection will be handled in the digital clusters. 10. In the section that discusses appropriate methods for exposure and outcome variables, the authors state that participants will be blinded to the study hypothesis to avoid social desirability responses. While I understand the desire to minimize information bias, this seems to be both problematic from an ethical standpoint (informed consent) but also stands in opposition to the authors statements throughout the paper of creating a transparent process. It is also unclear how the authors propose to do this since participants are also giving a saliva sample. Minor Concerns 1. In line 440, it is unclear what an HIV orientation test is, this reads like a typo. 2. In lines 490-491, “pre-determined time sloths” should read “pre-determined time slots” ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Jeremy Franklin Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 1 |
Prevalence and associated risk factors of HIV infections in a representative transgender and non-binary population in Flanders and Brussels (Belgium): Protocol for a community-based, cross-sectional study using time-location sampling PONE-D-21-25105R1 Dear Dr. De Brier, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Hong-Van Tieu Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
Formally Accepted |
PONE-D-21-25105R1 Prevalence and associated risk factors of HIV infections in a representative transgender and non-binary population in Flanders and Brussels (Belgium): Protocol for a community-based, cross-sectional study using time-location sampling Dear Dr. De Brier: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Hong-Van Tieu Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .